Hyperthermia and Olaparib in Treating Breast Cancer Patients With Chest Wall Recurrences
Status:
Active, not recruiting
Trial end date:
2023-10-01
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and best dose of olaparib when given with
hyperthermia in treating patients with breast cancer that has come back in the chest wall.
Olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell
growth. Hyperthermia treatment may kill or damage tumor cells by heating them to several
degrees above normal body temperature. Giving olaparib and hyperthermia treatment may work
better in treating patients with breast cancer that has come back in the chest well compared
to standard of care.